Press Release – New York, NY – June 23, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, in its recently priced $4.25 million securities purchase agreement with an accredited investor.
The SRFC team congratulates Chris Cooper, Chief Executive Officer of Shuttle Pharmaceuticals, on the transaction.
The SRFC team was led by partners Ross Carmel and Jeffrey Cahlon, with associate Soumya Cheedi.
